Unlike regular chemotherapy, rituxan does not cause low blood counts or hair loss.
和常规化疗不同的是,美罗华不导致血细胞减少或脱发。
Rituxan is currently approved as a treatment for non-Hodgkin's lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis.
Rituxan现在已经被批准用于非霍奇金淋巴瘤、慢性淋巴细胞白血病和风湿性关节炎的治疗。
Patients receiving Rituxan had a higher rate of infections at 37%, compared with 22% in the group of patients who didn't receive Rituxan as maintenance therapy.
但是服用Rituxan的病人受感染的几率为37%,高于没有服用Rituxan的病人的22%。
应用推荐